# APACT (NCT01964430)

> Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)

No report yet. It can be ordered.

- Drugs tested: nab-paclitaxel
- Indication: resected pancreatic ductal adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01964430
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Celgene
- Conditions: Pancreatic Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Digestive System Diseases; Endocrine System Diseases; Gemcitabine; Antimetabolites, Antineoplastic
- Interventions: nab-Paclitaxel; Gemcitabine
- Enrollment: 866
- Primary outcome: Kaplan Meier Estimate for Disease Free Survival (DFS) According to the Independent Radiological Review Committee

## Indexed commentary on APACT so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 44
- YouTube: 2
- Podcasts: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=apact-nct01964430

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01964430", "email": "<work email>"}; the inbox owner confirms by the emailed link.